Brodalumab
Brand Names: Siliq
Methodology & AI Transparency ⓘ
Brodalumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage siliq: ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 8 anonymous logs for Brodalumab (RxNorm 1872256).
- 3 Typical cash cost range: Dispensing cost comparison spans $90.31 mail/discount cash up to $221.26 uninsured retail (federal NADAC $2.0200).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Brodalumab include nausea (11%), headache (9.6%), diarrhea (8.3%).
Ask our AI Specialists anything about Brodalumab
Brodalumab Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage siliq: ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is a human interleukin-17 receptor A (IL-17RA) antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. ( 1 )
12.1 Mechanism of Action Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL-17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.
Pharmacokinetic profiling of Brodalumab demonstrates an elimination half-life of Biphasic clearance with 5–14 hr terminal t½ under Brodalumab maintenance with Complete (~100%) parenteral systemic delivery for Brodalumab (210 mg/1 Injection) systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (brodalumab), reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after brodalumab administration.
Titration schedules for Brodalumab (210 mg/1 Injection → 210 mg) require excluding 4 contraindications siliq is contraindicated in patients with:; crohn’s disease because siliq may cause worsening of disease .; clinically significant hypersensitivity to brodalumab or to any of the excipients in siliq or component of the container.; real-world patient logs highlight nausea (11% of reports), headache (9.6% of reports), fatigue (8.7% of reports) alongside a 91.00% Worth-It consensus.
Avoid overlapping interleukin-17 receptor a antagonist prescriptions alongside Brodalumab to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Brodalumab dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS SILIQ is contraindicated in patients with:
- Crohn’s disease because SILIQ may cause worsening of disease .
- Clinically significant hypersensitivity to brodalumab or to any of the excipients in SILIQ or component of the container.
Logged Side-Effect Incidence (8 Reports)
Brodalumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Brodalumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Brodalumab in psoriatic arthritis: results from the randomised phase III: What a 962-Participant Study Found Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Annals of the rheumatic diseases • 2021-02-15 • Phase III Randomized Trial | N = 962 | 93/100 | PMID 33106286 ↗ |
| Can This Approach Help? Inside the Latest Research on Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68 weeks. Rheumatology (Oxford, England) • 2023-05-02 • Phase III Randomized Trial | N = 77 | 88/100 | PMID 36130275 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploratory MRI and Clinical Marker Analysis of Pustulotic Arthro-Osteitis Further external validation is warranted, and additional clinical indicators are needed to predict disease activity. The Journal of dermatology • 2026-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42543660 ↗ |
| Can This Approach Help? Inside the Latest Research on Complete clearance and Psoriasis Area and Severity Index response for brodalumab Treatment with brodalumab was associated with higher levels of complete clearance and greater cumulative benefit over time compared with ustekinumab, in patients with moderate-to-severe psoriasis, regardless of prior treatment... Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34076919 ↗ |
Brodalumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.0200/unit (~$60.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $221.26 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $90.31 / mo | View logs ↓ |
Brodalumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Brodalumab RxNorm Concept ID | 1872256 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.0200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $221.26 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $90.31 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Brodalumab Patient Community, Cohort Filters & Dosage Logs
Deterministic Brodalumab reference combining NIH RxNorm (1872256), Medicaid NADAC ($2.0200/unit), and anonymous cohort outcomes (91% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Brodalumab community threads and patient logs by age, biological sex, dosage, and treatment duration.